A Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of Aclidinium Bromide 400 μg Bid on COPD Symptoms and Sleep Quality After 3 Weeks of Treatment in Patients With Stable Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
Clinical trial NCT02153489 · COMPLETED
Trial details
- NCT number
- NCT02153489
- Sponsor
- AstraZeneca
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2014-04-01
- Primary completion
- 2015-06-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.